Children with sickle cell disease have a 600-fold increased incidence of invasive pneumococcal disease. Platelet-activating factor receptor (PAFr) mediates pneumococcal invasion, and up-regulation of PAFr on chronically activated endothelia could contribute to increased bacterial invasion. Mice transplanted with sickle cell bone marrow developed more extensive infection, and 57% died, compared with 16% of wild-type mice. Histopathological analysis revealed that sickle cell mice expressed significantly more PAFr on endothelia and epithelia. Pharmacological blockade or genetic deletion of PAFr protected sickle cell mice from mortality. We conclude that PAFr plays an important role in hypersusceptibility to pneumococcal infection in sickle cell disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1086/510626 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Scoping Review on Sex and Gender Differences in the Adverse Health Outcomes of Individuals with Sickle Cell Trait.
Womens Health Rep (New Rochelle)
December 2024
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Although there is an emerging body of evidence that addresses the adverse health outcomes of individuals with sickle cell trait (SCT), it is not clear if the findings are generalizable from a sex and gender perspective. The purpose of this scoping review was to complete an assessment of main concepts, identify knowledge gaps, and determine the potential value of conducting an eventual systematic review. The research question guiding this scoping review is: In SCT individuals with adverse health outcomes, what is known about sex and gender differences? We conducted a scoping review of research on SCT from 2016 to 2022 across five databases, with 36 research studies included in the review.
View Article and Find Full Text PDFMYB represses ζ-globin expression through upregulating ETO2.
Acta Biochim Biophys Sin (Shanghai)
January 2025
Innovation Center for Diagnostics and Treatment of Thalassemia, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Reactivating the embryonic ζ-globin gene represents a potential therapeutic approach to ameliorate the severe clinical phenotype of α-thalassemia and sickle cell disease. The transcription factor MYB has been extensively proven to be a master regulator of the γ-globin gene, but its role in the regulation of ζ-globin remains incompletely understood. Here, we report a mechanistic study on the derepression of ζ-globin both and .
View Article and Find Full Text PDFRe-energising therapy options in sickle cell disease: the mitapivat phase 2 trial results.
Lancet Haematol
January 2025
St Jude Children's Research Hospital, Memphis, TN 38107, USA. Electronic address:
The Interplay Between Ophthalmic and Systemic Outcomes in Patients With Sickle Cell Disease and Concurrent Retinopathy-A Population-Based Study.
Am J Hematol
January 2025
Byers Eye Institute at Stanford University School of Medicine, Watson, Palo Alto, California, US.
Unveiling the Burden of Sickle Cell Anemia: A Pilot Study Validating Dried Blood Spots for Newborn Screening.
Indian J Pediatr
January 2025
Department of Biochemistry, All India Institute of Medical Sciences, Bibinagar, Hyderabad, Telangana, India.
This hospital-based cross-sectional study aimed to screen newborns for sickle cell anemia immediately after birth and validate dried blood spot (DBS) samples against conventional venous blood samples (CBS) for hemoglobin variant analysis by HPLC. Among 751 newborns, 2.93% were found to have sickle cell trait.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!